Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]

Detalles Bibliográficos
Autores principales: Deng, Linglong, Petrek, Hannah, Tu, Mei-Juan, Batra, Neelu, Yu, Ai-Xi, Yu, Ai-Ming
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Correction
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465936/
https://www.ncbi.nlm.nih.gov/pubmed/37655312
http://dx.doi.org/10.1016/j.apsb.2023.07.002
_version_ 1785098774943629312
author Deng, Linglong
Petrek, Hannah
Tu, Mei-Juan
Batra, Neelu
Yu, Ai-Xi
Yu, Ai-Ming
author_facet Deng, Linglong
Petrek, Hannah
Tu, Mei-Juan
Batra, Neelu
Yu, Ai-Xi
Yu, Ai-Ming
author_sort Deng, Linglong
collection PubMed
description
format Online
Article
Text
id pubmed-10465936
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-104659362023-08-31 Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965] Deng, Linglong Petrek, Hannah Tu, Mei-Juan Batra, Neelu Yu, Ai-Xi Yu, Ai-Ming Acta Pharm Sin B Correction Elsevier 2023-08 2023-07-05 /pmc/articles/PMC10465936/ /pubmed/37655312 http://dx.doi.org/10.1016/j.apsb.2023.07.002 Text en © 2023 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Correction
Deng, Linglong
Petrek, Hannah
Tu, Mei-Juan
Batra, Neelu
Yu, Ai-Xi
Yu, Ai-Ming
Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
title Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
title_full Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
title_fullStr Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
title_full_unstemmed Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
title_short Author correction to ‘Bioengineered miR-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [Acta Pharmaceutica Sinica B 11 (2021) 3950–3965]
title_sort author correction to ‘bioengineered mir-124-3p prodrug selectively alters the proteome of human carcinoma cells to control multiple cellular components and lung metastasis in vivo’ [acta pharmaceutica sinica b 11 (2021) 3950–3965]
topic Correction
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10465936/
https://www.ncbi.nlm.nih.gov/pubmed/37655312
http://dx.doi.org/10.1016/j.apsb.2023.07.002
work_keys_str_mv AT denglinglong authorcorrectiontobioengineeredmir1243pprodrugselectivelyalterstheproteomeofhumancarcinomacellstocontrolmultiplecellularcomponentsandlungmetastasisinvivoactapharmaceuticasinicab11202139503965
AT petrekhannah authorcorrectiontobioengineeredmir1243pprodrugselectivelyalterstheproteomeofhumancarcinomacellstocontrolmultiplecellularcomponentsandlungmetastasisinvivoactapharmaceuticasinicab11202139503965
AT tumeijuan authorcorrectiontobioengineeredmir1243pprodrugselectivelyalterstheproteomeofhumancarcinomacellstocontrolmultiplecellularcomponentsandlungmetastasisinvivoactapharmaceuticasinicab11202139503965
AT batraneelu authorcorrectiontobioengineeredmir1243pprodrugselectivelyalterstheproteomeofhumancarcinomacellstocontrolmultiplecellularcomponentsandlungmetastasisinvivoactapharmaceuticasinicab11202139503965
AT yuaixi authorcorrectiontobioengineeredmir1243pprodrugselectivelyalterstheproteomeofhumancarcinomacellstocontrolmultiplecellularcomponentsandlungmetastasisinvivoactapharmaceuticasinicab11202139503965
AT yuaiming authorcorrectiontobioengineeredmir1243pprodrugselectivelyalterstheproteomeofhumancarcinomacellstocontrolmultiplecellularcomponentsandlungmetastasisinvivoactapharmaceuticasinicab11202139503965

Ejemplares similares